Trusted Resource for Clinical Trials, Protocols & Progress
Sponsors should select CRO partners based on demonstrated compliance history, quality management systems, and capacity to manage complex multinational trials. Conducting audits before contract award, providing training support, and establishing clear KPIs for monitoring and data integrity are essential. Building long-term partnerships with CROs enhances accountability and reduces trial risks.
Click to read the full article.
Contract manufacturing in Indian clinical trials is no longer limited to cost efficiencies—it is a strategic enabler of speed, compliance, and scalability. With proper licensing, GMP adherence, and sponsor oversight, Indian CDMOs can significantly contribute to global drug development programs while aligning with CDSCO and international expectations. Sponsors must ensure robust due diligence, clear quality agreements, and strong monitoring to leverage the full potential of contract manufacturing in clinical research.
Click to read the full article.
MHRA clinical data submission requirements in the UK demand rigorous planning, data integrity, and adherence to GCP and eCTD standards. Sponsors, CROs, and investigators must ensure that CTAs, amendments, safety reports, and trial results are complete, accurate, and transparent. By maintaining robust documentation, engaging proactively with regulators, and adopting best practices in electronic submissions, sponsors can achieve regulatory approval while ensuring patient safety and scientific credibility. As the UK refines its post-Brexit clinical research framework, submission quality and compliance will remain decisive factors in successful drug development programmes.
Click to read the full article.
Safety reporting nuances apply in specific trial types:
Pediatric Trials: Additional vigilance is required due to unique adverse event profiles.
Oncology Trials: High SAE incidence demands efficient reporting workflows and rapid response systems.
Rare Diseases: Small populations mean each adverse event significantly impacts benefit-risk evaluation.
Decentralized Trials: Digital adverse event capture requires rigorous validation to ensure timely safety reporting.
The TMF is more than a regulatory requirement—it’s a real-time indicator of a trial’s integrity, conduct, and compliance. With growing CDSCO scrutiny and global trial participation, Indian sponsors, CROs, and investigators must embrace standardized, audit-ready TMF practices. Whether managed on paper or electronically, a well-maintained TMF safeguards data credibility, protects patient rights, and ensures long-term regulatory alignment in the dynamic landscape of Indian clinical research.
Click to read the full article.
Sponsors should plan for competitive recruitment landscapes in Tier-1 hospitals by including Tier-2 sites in their strategies. Early engagement with the NMPA through Breakthrough or Conditional Approval pathways can accelerate timelines. Establishing strong pharmacovigilance systems and integrating RWE into protocols can enhance regulatory success and patient access.
Click to read the full article.
NHS patient registries provide a powerful mechanism for improving clinical trial recruitment efficiency, diversity, and scientific validity in the UK. When used ethically and in compliance with MHRA, HRA, and GDPR requirements, registries enable sponsors to access diverse patient populations while ensuring participant confidentiality and trust. Sponsors and CROs should implement robust SOPs, transparent communication, and secure IT systems to maximise the benefits of registry-based recruitment in modern UK clinical research.
Click to read the full article.
ATMP oversight raises unique challenges:
Oncology ATMPs: CAR-T cell therapies require hospital accreditation and specialized handling protocols.
Rare Diseases: Small patient populations necessitate cross-border collaboration and centralized registries.
Decentralized Trials: EMA requires validation of digital tools for remote monitoring and long-term follow-up.
First-in-Human Trials: Require enhanced regulatory scrutiny and risk mitigation strategies due to high uncertainty.
Sponsors should adopt best practices such as engaging early with the NMPA, preparing robust pharmacovigilance systems, and designing culturally appropriate informed consent processes. Including Tier-2 hospitals in vaccine trials expands access to diverse populations. Collaboration with CROs and public health authorities ensures smooth operations and compliance.
Click to read the full article.
India’s CDSCO has shown commendable adaptability in enabling accelerated access to critical therapies, especially during emergencies like COVID-19. Through a blend of NDCTR provisions, ad hoc guidances, and reliance on foreign approvals, the regulatory system supports both innovation and patient safety. However, fast-tracking is not a shortcut—it requires rigorous data, strategic planning, and robust post-approval controls. Sponsors who prepare proactively and align with CDSCO expectations stand to benefit from faster timelines without regulatory compromise.
Click to read the full article.
